IPH-6501
- Generic Name
- IPH-6501
Phase1/2 Study of IPH6501 in Patients With Relapsed /Refractory B-Cell Non-Hodgkin Lymphoma
- First Posted Date
- 2023-10-18
- Last Posted Date
- 2025-04-02
- Lead Sponsor
- Innate Pharma
- Target Recruit Count
- 184
- Registration Number
- NCT06088654
- Locations
- 🇺🇸
Icahn School Of Medicine At Mount Sinai, New York, New York, United States
🇫🇷Hôpital de la Coception, Marseille, France
🇺🇸City of Hope, Duarte, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath